WO1999048483A8 - (-)-phenylpropanolamine en tant que medicament sympathomimetique - Google Patents

(-)-phenylpropanolamine en tant que medicament sympathomimetique

Info

Publication number
WO1999048483A8
WO1999048483A8 PCT/US1999/002023 US9902023W WO9948483A8 WO 1999048483 A8 WO1999048483 A8 WO 1999048483A8 US 9902023 W US9902023 W US 9902023W WO 9948483 A8 WO9948483 A8 WO 9948483A8
Authority
WO
WIPO (PCT)
Prior art keywords
phenylpropanolamine
present
substantially free
sympathomimetic drug
methods
Prior art date
Application number
PCT/US1999/002023
Other languages
English (en)
Other versions
WO1999048483A3 (fr
WO1999048483A2 (fr
Inventor
Anthony R Booth
William Sherman
Peter Raven
James L Caffrey
Thomas Yorio
Michael Forster
Patricia Gwirtz
Original Assignee
Warner Lambert Co
Anthony R Booth
William Sherman
Peter Raven
James L Caffrey
Thomas Yorio
Michael Forster
Patricia Gwirtz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Anthony R Booth, William Sherman, Peter Raven, James L Caffrey, Thomas Yorio, Michael Forster, Patricia Gwirtz filed Critical Warner Lambert Co
Priority to AU24865/99A priority Critical patent/AU2486599A/en
Priority to CA002305294A priority patent/CA2305294A1/fr
Publication of WO1999048483A2 publication Critical patent/WO1999048483A2/fr
Publication of WO1999048483A3 publication Critical patent/WO1999048483A3/fr
Publication of WO1999048483A8 publication Critical patent/WO1999048483A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques qui comprennent de la (-)-phénylpropanolamine et un excipient acceptable sur le plan pharmaceutique, dans lesquelles la (-)-phénylpropanolamine ne contient pratiquement pas de (+)-phénylpropanolamine. Dans une autre réalisation, la présente invention concerne des procédés de suppression de congestions nasale et bronchique et inducteur de dilatation de pupille par administration, à un mammifère, d'une quantité thérapeutiquement efficace de (-)-phénylpropanolamine. La (-)-phénylpropanolamine utilisée dans ces procédés ne contient pratiquement pas de (+)-phénylpropanolamine et ne présente pas les effets secondaires néfastes associés au traitement avec la (+)-phénylpropanolamine.
PCT/US1999/002023 1998-03-23 1999-01-28 (-)-phenylpropanolamine en tant que medicament sympathomimetique WO1999048483A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU24865/99A AU2486599A (en) 1998-03-23 1999-01-28 (-)-phenylpropanolamine as a sympathomimetic drug
CA002305294A CA2305294A1 (fr) 1998-03-23 1999-01-28 (-)-phenylpropanolamine en tant que medicament sympathomimetique

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7895098P 1998-03-23 1998-03-23
US60/078,950 1998-03-23
US9145298P 1998-07-01 1998-07-01
US60/091,452 1998-07-01

Publications (3)

Publication Number Publication Date
WO1999048483A2 WO1999048483A2 (fr) 1999-09-30
WO1999048483A3 WO1999048483A3 (fr) 2000-01-06
WO1999048483A8 true WO1999048483A8 (fr) 2000-03-02

Family

ID=26761154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/002023 WO1999048483A2 (fr) 1998-03-23 1999-01-28 (-)-phenylpropanolamine en tant que medicament sympathomimetique

Country Status (3)

Country Link
AU (1) AU2486599A (fr)
CA (1) CA2305294A1 (fr)
WO (1) WO1999048483A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4818541A (en) * 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
WO1991017746A1 (fr) * 1990-05-21 1991-11-28 Norwich Eaton Pharmaceuticals, Inc. Utilisation de phenylpropanolamine comme secretagogue muqueux des voies respiratoires superieures
AU7576798A (en) * 1997-05-15 1998-12-08 Warner-Lambert Company Sympathomimetic compounds

Also Published As

Publication number Publication date
CA2305294A1 (fr) 1999-09-30
WO1999048483A3 (fr) 2000-01-06
AU2486599A (en) 1999-10-18
WO1999048483A2 (fr) 1999-09-30

Similar Documents

Publication Publication Date Title
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
NZ527113A (en) Rapid-onset medicament for the treatment of sexual dysfunction
WO2000021515A3 (fr) Codeine intra-nasale permettant d'eliminer rapidement la toux et de soulager rapidement la douleur
ID29181A (id) Kombinasi formoterol dan garam tiotropium
WO2002038171A3 (fr) METHODES DE TRAITEMENT DE MALADIES CAUSEES PAR DES DEFICITS EN α-L-IDURONIDASE RECOMBINEE
ATE329608T1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
NZ510887A (en) Formulations of fexofenadine for ocular and nasal delivery
EP0966966A3 (fr) Forme posologique de néfadozone
IL124977A0 (en) Oral administration of effective amounts of forms of hyaluronic acid
WO2002089778A3 (fr) Systeme therapeutique transdermique destine au traitement de la maladie de parkinson induisant des niveaux de plasma eleves de rotigotine
WO2005058233A3 (fr) Methodes de traitement d'une pancreatite aigue
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
CA2459470A1 (fr) Composition pharmaceutique comprenant de la gabapentine ou un analogue de celle-ci et un .alpha.-aminoamide, et utilisation analgesique de ladite composition
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
CA2433833A1 (fr) Utilisation de flumazenil dans l'elaboration d'un medicament visant a traiter la dependence a l'alcool
WO2001010387A3 (fr) Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral
HK1024631A1 (en) Use of (+) mefloquine for the treatment of malaria
WO2005044186A3 (fr) Formulations pharmaceutiques destinees a etre inhalees utilisant des agents dessechants et methodes d'administration desdites formulations pharmaceutiques
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
EP0799618A3 (fr) Utilisation d'antagonistes de l'adrénorécepteur alpha 1 dans la fabrication d'unmédicament pur la prévention et au traitment du cancer
CA2519789A1 (fr) Aplidine utilisee dans le traitement du myelome multiple
WO1999048483A3 (fr) (-)-phenylpropanolamine en tant que medicament sympathomimetique
HUP0402062A2 (hu) Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HR HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HR HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HR HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 39/99 UNDER (81) ADD "US"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase in:

Ref document number: 2305294

Country of ref document: CA

Ref country code: CA

Ref document number: 2305294

Kind code of ref document: A

Format of ref document f/p: F

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 24865/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999904471

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999904471

Country of ref document: EP

122 Ep: pct application non-entry in european phase